For years, little was known of the typhoid burden in Africa, even though outbreaks of multi-drug resistant typhoid is becoming increasingly common. This lack of information spurred the Bill and Melinda Gates Foundation to fund the Typhoid Fever Surveillance in Africa Program (TSAP) through the International Vaccine Institute, a first-of-its-kind study established to shed light on true extent of the typhoid burden and multi-drug resistance distribution on the continent. The results from the TSAP, recently published in the Lancet Global Health, represent the most comprehensive and rigorous analysis of typhoid in Africa and could change our understanding of the disease burden across the continent.

Vaccines are healthcare’s first line of defense. From polio to pertussis, rubella to rotavirus, vaccination has saved more lives than any other medical advance in recent history.

An estimated two billion people lack the medicines they need. The 2016 Access to Medicines Index analyzes pharmaceutical companies’ efforts to improve access to medicines, vaccines and diagnostics for low- and middle-income countries.

As 2016 has come to a close, our team at the Coalition against Typhoid would like to take a moment to reflect on this busy year. It was a year that illustrated, more clearly than ever, that typhoid is a continuing and major threat to millions around the world. Over the course of 2016, an estimated 21 million people – most of them children – suffered from typhoid. Of these, 220,000 died of the disease. We saw typhoid outbreaks in Malawi, Fiji, Zimbabwe and other countries. In endemic countries like India and Nepal, the monsoon season worsened the impact of this disease. In 2016, typhoid struck at ordinary places like schools and weddings, and also at the most vulnerable places, such as refugee camps, reminding us that this disease doesn’t discriminate.